SAB Biotherapeutics CFO Michael King to Depart for CEO Role at Oncology Firm
SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company, announced that Chief Financial Officer Michael King will leave his position on June 4 to become CEO of a private oncology firm. King will continue to advise SAB until the end of the year. The Board of Directors has initiated a search...